Advanced dementia, Quality of Life, Paracetamol, long-term care facility Gevorderde dementie, Kwaliteit van leven, Paracetamol, verpleeghuis
Conditions
Interventions
Subjects will receive either orally administered paracetamol at a maximum dose of 3 grams (3 x 2 tablets of 500 mg each) daily for 4 weeks, followed by 2 weeks 2.5 grams, according to recent protocols
Sponsors
Leiden University Medical Center (LUMC)
Eligibility
Inclusion criteria
Inclusion criteria: Diagnosis of dementia, Reisberg Global Deterioration Scale 5-7 Age 65 years or older QUALIDEM (Quality of life) score below the expected median score of 70) Not using any pain medication one week before start study. Residents with PRN prescribed paracetamol ("as needed") are also eligible, if the use of paracetamol in the last week was not more than 1 gram/day and less than 3 grams/week
Exclusion criteria
Exclusion criteria: Presence of a severe psychiatric disorder, Severe liver insufficiency/disease, Use of >4 units alcohol per day, Allergy to study drugs, Concomitant use of flucloxacillin, carbamazepine, fenytoïne, fenobarbital, isoniazide and/or rifampicine, Weight < 50 kg
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life: QUALIDEM, DS-DAT | — |
Secondary
| Measure | Time frame |
|---|---|
| Neuropsychiatric symptoms of dementia (NPI-NH) ADL functioning (Katz-15) Care dependency (CDS) Pain (MOBID-2) Medication use | — |
Contacts
Public ContactP.H. Dam, van
Department of Public Health and Primary Care, Postzone V-0-P
Outcome results
None listed